组蛋白去甲基化酶PHF8通过直接靶向BCR::ABL1促进慢性髓性白血病的发展
研究显示,植物同源结构域指蛋白8(PHF8)在慢性髓性白血病(CML)样本中较健康对照异常富集,可抑制CML细胞分化并促进增殖;PHF8敲低对甲磺酸伊马替尼(IM)耐药CML细胞的增殖抑制效应更强。机制上,PHF8作为转录调节因子与BCR::ABL1融合基因启动子相互作用,改变H3K9me1、H3K9me2和H3K27me1甲基化水平,促进BCR::ABL1转录。研究提示靶向PHF8是CML的有用治疗途径。
要点
- PHF8在CML样本中较健康对照异常富集,抑制CML细胞分化并促进增殖。
- PHF8敲低对IM耐药CML细胞的增殖抑制效应强于对非耐药细胞。
- PHF8与BCR::ABL1启动子结合,改变H3K9me1、H3K9me2、H3K27me1甲基化促进其转录。
核心结论
- 靶向直接调控BCR::ABL1表达的PHF8是CML的有用治疗途径。
研究设计与样本
- 研究比较了CML样本与健康对照中PHF8的富集情况,并在CML细胞中进行PHF8敲低功能实验。
主要发现
- PHF8在CML样本中较健康对照异常富集。
- PHF8抑制CML细胞分化并促进CML细胞增殖。
- PHF8敲低的增殖抑制功能对甲磺酸伊马替尼(IM)耐药CML细胞作用更强。
- PHF8作为转录调节因子与BCR::ABL1融合基因启动子相互作用,改变H3K9me1、H3K9me2和H3K27me1甲基化水平,促进BCR::ABL1转录。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukaemia (CML), TKI resistance remains a major challenge. Here, we demonstrated that plant homeodomain finger protein 8 (PHF8), a histone demethylase was aberrantly enriched in CML samples compared to healthy controls. PHF8 inhibited CML cell differentiation and promoted CML cell proliferation. Furthermore, the proliferation-inhibited function of PHF8-knockdown have stronger effect on imatinib mesylate (IM)-resistant CML cells. Mechanistically, we identified that PHF8 as a transcriptional modulator interacted with the promoter of the BCR::ABL1 fusion gene and alters the methylation levels of H3K9me1, H3K9me2 and H3K27me1, thereby promoting BCR::ABL1 transcription. Overall, our study suggests that targeting PHF8, which directly regulates BCR::ABL1 expression, is a useful therapeutic approach for CML.
引用
- Feng H, Fu Y, Cui Z, et al. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1. Br J Haematol. 2023. PMID: 37469124. doi:10.1111/bjh.18983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。